Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review

References

• Flegal KM. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–1727. doi:10.1001/jama.288.14.1723
   PubMed Web of Science ®Google Scholar
• Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2017–2018. Centers for Disease Control and Prevention; 2020. Available from: https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf. Accessed September 21, 2022.
   Google Scholar
• Fryar CD, Carroll MD, Afful J. Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Aged 20 and Over: United States, 1960–1962 Through 2017–2018. NCHS Health E-Stats; 2020.
   Google Scholar
• World Health Organization. Obesity and overweight; 2021. Avialable from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed September 21, 2022.
   Google Scholar
• Whitlock G, Lewington S, Sherliker P, et al.; Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083–1096.
   PubMed Web of Science ®Google Scholar
• Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944–953.
   PubMed Web of Science ®Google Scholar
• Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–e1010.
   PubMed Web of Science ®Google Scholar
• Rashid MN, Fuentes F, Touchon RC, Wehner PS. Obesity and the risk for cardiovascular disease. Prev Cardiol. 2003;6(1):42–47. PMID: 12624562. doi:10.1111/j.1520-037x.2003.01358.x
   Google Scholar
• Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990;322(13):882–889. doi:10.1056/NEJM199003293221303
   PubMed Web of Science ®Google Scholar
• Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67(5):968–977. doi:10.1161/01.cir.67.5.968
   PubMed Web of Science ®Google Scholar
• Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162(16):1867–1872. PMID: 12196085. doi:10.1001/archinte.162.16.1867
   PubMedGoogle Scholar
• James WP, Caterson ID, Coutinho W, et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917.
   PubMed Web of Science ®Google Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–588.
   PubMed Web of Science ®Google Scholar
• Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets. Prescribing information; 2021. Available from: https://contrave.com/contrave-pi/. Accessed September 21, 2022.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. PMID: 33782057; PMCID: PMC8005924. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Afshari R, Khadem-Rezaiyan M, Khatibi Moghadam H, Talebi M. Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety. Toxicol Res. 2019;36(1):21–27. PMID: 32042711; PMCID: PMC6990297. doi:10.1007/s43188-019-00008-2
   Web of Science ®Google Scholar
• Aghabiklooei A, Hassanian-Moghaddam H, Zamani N, et al. Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naive methadone-intoxicated patients. Biomed Res Int. 2013;2013:903172. PMID: 24089691; PMCID: PMC3781921. doi:10.1155/2013/903172
   Web of Science ®Google Scholar
• Ahmadi J, Sahraian A, Biuseh M. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving. Trials. 2019;20(1):468. PMID: 31362784; PMCID: PMC6668115. doi:10.1186/s13063-019-3554-6
   PubMed Web of Science ®Google Scholar
• Caponnetto P, DiPiazza J, Cappello GC, Demma S, Maglia M, Polosa R. Multimodal smoking cessation in a real-life setting: combining motivational interviewing with official therapy and reduced risk products. Tob Use Insights. 2019;12:1179173X19878435. PMID: 31636483; PMCID: PMC6783661. doi:10.1177/1179173X19878435
   Web of Science ®Google Scholar
• Chevassus H, Farret A, Gagnol JP, et al. Psychological and physiological effects of bupropion compared to methylphenidate after prolonged administration in healthy volunteers (NCT00285155). Eur J Clin Pharmacol. 2013;69(4):779–787. PMID: 23052417. doi:10.1007/s00228-012-1418-z.
   PubMed Web of Science ®Google Scholar
• Cox LS, Nollen NL, Mayo MS, et al. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. J Natl Cancer Inst. 2012;104(4):290–298. PMID: 22282543; PMCID: PMC3283533. doi:10.1093/jnci/djr513
   PubMedGoogle Scholar
• Darpo B, Zhou M, Bai SA, Ferber G, Xiang Q, Finn A. Differentiating the effect of an opioid agonist on cardiac repolarization from μ-receptor-mediated, indirect effects on the qt interval: a randomized, 3-way crossover study in healthy subjects. Clin Ther. 2016;38(2):315–326. PMID: 26749217. doi:10.1016/j.clinthera.2015.12.004
   PubMed Web of Science ®Google Scholar
• Gelderblom H, Wüstenberg T, McLean T, et al. Bupropion for the treatment of apathy in Huntington’s disease: a multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial. PLoS One. 2017;12(3):e0173872. PMID: 28323838; PMCID: PMC5360242. doi:10.1371/journal.pone.0173872
   PubMed Web of Science ®Google Scholar
• Gonzales P, Grieco A, White E, et al. Safety of oral naltrexone in HIV-positive men who have sex with men and transgender women with alcohol use disorder and initiating antiretroviral therapy. PLoS One. 2020;15(3):e0228433. PMID: 32134956; PMCID: PMC7058313. doi:10.1371/journal.pone.0228433
   Web of Science ®Google Scholar
• Gray KM, Carpenter MJ, Lewis AL, Klintworth EM, Upadhyaya HP. Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. Nicotine Tob Res. 2012;14(2):234–239. PMID: 21778151; PMCID: PMC3265741. doi:10.1093/ntr/ntr130
   PubMed Web of Science ®Google Scholar
• Gulrez G, Badyal DK, Deswal RS, Sharma A. Bupropion as an augmenting agent in patients of depression with partial response. Basic Clin Pharmacol Toxicol. 2012;110(3):227–230. PMID: 21895979. doi:10.1111/j.1742-7843.2011.00788.x
   PubMed Web of Science ®Google Scholar
• Heinzerling KG, Gadzhyan J, van Oudheusden H, Rodriguez F, McCracken J, Shoptaw S. Pilot randomized trial of bupropion for adolescent methamphetamine abuse/dependence. J Adolesc Health. 2013;52(4):502–505. PMID: 23333007; PMCID: PMC3608805. doi:10.1016/j.jadohealth.2012.10.275
   PubMed Web of Science ®Google Scholar
• King AC, Cao D, O’Malley SS, et al. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women. J Clin Psychopharmacol. 2012;32(5):630–636. PMID: 22926596; PMCID: PMC4640209. doi:10.1097/JCP.0b013e3182676956
   PubMed Web of Science ®Google Scholar
• Korthuis PT, Lum PJ, Vergara-Rodriguez P, et al.; CTN-0055 CHOICES Investigators. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction. 2017;112(6):1036–1044. PMID: 28061017; PMCID: PMC5408318. doi:10.1111/add.13753
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69(9):973–981. PMID: 22945623; PMCID: PMC3614358. doi:10.1001/archgenpsychiatry.2012.1a
   PubMed Web of Science ®Google Scholar
• Lee JD, McDonald R, Grossman E, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction. 2015;110(6):1008–1014. PMID: 25703440. doi:10.1111/add.12894
   Web of Science ®Google Scholar
• Ling W, Hillhouse MP, Saxon AJ, et al. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016;111(8):1416–1427. PMID: 26948856; PMCID: PMC4940267. doi:10.1111/add.13375
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Monico LB, Gryczynski J, Fishman MJ, O’Grady KE, Schwartz RP. Extended-release naltrexone for youth with opioid use disorder. J Subst Abuse Treat. 2021;130:108407. PMID: 34118699; PMCID: PMC8478707. doi:10.1016/j.jsat.2021.108407
   PubMed Web of Science ®Google Scholar
• Nasr S, Wendt B, Popli A, Crayton J. Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion. J Affect Disord. 2014;162:50–54. PMID: 24767005. doi:10.1016/j.jad.2014.03.019
   Web of Science ®Google Scholar
• O’Malley SS, Corbin WR, Leeman RF, et al. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. J Clin Psychiatry. 2015;76(2):e207–13. PMID: 25742208; PMCID: PMC4442987. doi:10.4088/JCP.13m08934
   PubMed Web of Science ®Google Scholar
• Oslin DW, Leong SH, Lynch KG, et al. Naltrexone vs placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA Psychiatry. 2015;72(5):430–437. PMID: 25760804.10.4088/JCP.13m08934. PMID: 25742208; PMCID: PMC4442987. doi:10.1001/jamapsychiatry.2014.3053
   PubMed Web of Science ®Google Scholar
• Pathak S, Vince B, Kelsh D, et al. Abuse potential of samidorphan: a Phase I, oxycodone-, pentazocine-, naltrexone-, and placebo-controlled study. J Clin Pharmacol. 2019;59(2):218–228. PMID: 30476361. doi:10.1002/jcph.1343
   Web of Science ®Google Scholar
• Ray LA, Bujarski S, Courtney KE, et al. The effects of naltrexone on subjective response to methamphetamine in a clinical sample: a double-blind, placebo-controlled laboratory study. Neuropsychopharmacology. 2015;40(10):2347–2356. PMID: 25801501; PMCID: PMC4538349. doi:10.1038/npp.2015.83
   PubMed Web of Science ®Google Scholar
• Salehifar E, Azimi S, Janbabai G, et al. Efficacy and safety of bupropion in cancer-related fatigue, a randomized double blind placebo controlled clinical trial. BMC Cancer. 2020;20(1):158. PMID: 32106832; PMCID: PMC7045731. doi:10.1186/s12885-020-6618-9
   Web of Science ®Google Scholar
• Santos GM, Coffin P, Santos D, et al. Feasibility, acceptability, and tolerability of targeted naltrexone for nondependent methamphetamine-using and binge-drinking men who have sex with men. J Acquir Immune Defic Syndr. 2016;72:21–30. PMID: 26674372; PMCID: PMC4837026. doi:10.1097/QAI.0000000000000922
   PubMed Web of Science ®Google Scholar
• Schmahl C, Kleindienst N, Limberger M, et al. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol. 2012;27(1):61–68. PMID: 22002175. doi:10.1097/YIC.0b013e32834d0e50
   PubMed Web of Science ®Google Scholar
• Siddiqi K, Khan A, Ahmad M, et al. Action to stop smoking in suspected tuberculosis (ASSIST) in Pakistan: a cluster randomized, controlled trial. Ann Intern Med. 2013;158(9):667–675. PMID: 23648948. doi:10.7326/0003-4819-158-9-201305070-00006
   PubMed Web of Science ®Google Scholar
• Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: a pilot study. J Clin Gastroenterol. 2013;47(4):339–345. PMID: 23188075; PMCID: PMC3586944. doi:10.1097/MCG.0b013e3182702f2b
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Bhide P, Zhu J, et al. The mixed opioid receptor antagonist naltrexone mitigates stimulant-induced euphoria: a double-blind, placebo-controlled trial of naltrexone. J Clin Psychiatry. 2018b;79(2):17m11609. PMID: 29617066; PMCID: PMC6548180. doi:10.4088/JCP.17m11609
   Web of Science ®Google Scholar
• Tanum L, Solli KK, Latif ZE, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197–1205. PMID: 29049469; PMCID: PMC6583381. doi:10.1001/jamapsychiatry.2017.3206
   PubMed Web of Science ®Google Scholar
• Taveira TH, Wu WC, Tschibelu E, et al. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study. J Psychopharmacol. 2014;28(4):395–400. PMID: 24218048. doi:10.1177/0269881113509904
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Krupitsky E, Verbitskaya E, et al. Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry. 2012;169(5):531–536. PMID: 22764364. doi:10.1176/appi.ajp.2011.11071121
   PubMed Web of Science ®Google Scholar
• White MA, Grilo CM. Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74(4):400–406. PMID: 23656848; PMCID: PMC4021866. doi:10.4088/JCP.12m08071
   PubMed Web of Science ®Google Scholar
• Xuyi W, Juelu W, Xiaojun X, et al. Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence. Am J Addict. 2014;23(2):162–169. PMID: 24107112. doi:10.1111/j.1521-0391.2013.12085.x
   Web of Science ®Google Scholar
• Yee A, Loh HS, Ong TA, Ng CG, Sulaiman AH; Randomized, Double-Blind, Parallel-Group. Placebo-controlled trial of bupropion as treatment for methadone-emergent sexual dysfunction in men. Am J Mens Health. 2018;12(5):1705–1718. PMID: 29973132; PMCID: PMC6142124. doi:10.1177/1557988318784152
   Web of Science ®Google Scholar
• Adhikari S, Tulachan P, Ojha SP, Chapagai M, Dhungana S, Pant SB. Comparison of disulfiram and naltrexone in cases of alcohol dependence syndrome. J Nepal Health Res Counc. 2020;18(1):75–81. PMID: 32335597. doi:10.33314/jnhrc.v18i1.1921
   Google Scholar
• Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–2520. PMID: 27116918. doi:10.1016/S0140-6736(16)30272-0
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al.; COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21(5):935–943. PMID: 23408728; PMCID: PMC3739931. doi:10.1002/oby.20309
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018;178(5):622–631. PMID: 29630702; PMCID: PMC6145797. doi:10.1001/jamainternmed.2018.0397
   PubMed Web of Science ®Google Scholar
• Bisaga A, Mannelli P, Yu M, et al. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial. Drug Alcohol Depend. 2018;187:171–178. PMID: 29674251. doi:10.1016/j.drugalcdep.2018.02.023
   PubMed Web of Science ®Google Scholar
• Carney G, Bassett K, Maclure M, Taylor S, Dormuth CR. Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. Addiction. 2020;115(8):1534–1546. PMID: 32077187. doi:10.1111/add.14951
   PubMed Web of Science ®Google Scholar
• Carney G, Maclure M, Malfair S, Bassett K, Wright JM, Dormuth CR. Comparative safety of smoking cessation pharmacotherapies during a government-sponsored reimbursement program. Nicotine Tob Res. 2021;23(2):302–309. PMID: 32484873. doi:10.1093/ntr/ntaa100
   Web of Science ®Google Scholar
• Chen AC, Huang KL, Chen HM, Chen PC, Chen VC, Chiu WC. Antidepressants and the risk of myocardial infarction among patients with diabetes: a population-based cohort study. J Affect Disord. 2021;294:109–114. PMID: 34274786. doi:10.1016/j.jad.2021.06.078
   Web of Science ®Google Scholar
• Cheon EJ, Lee KH, Park YW, et al. Comparison of the efficacy and safety of aripiprazole versus bupropion augmentation in patients with major depressive disorder unresponsive to selective serotonin reuptake inhibitors: a randomized, prospective, open-label study. J Clin Psychopharmacol. 2017;37(2):193–199. PMID: 28129308. doi:10.1097/JCP.0000000000000663
   PubMed Web of Science ®Google Scholar
• Cinciripini PM, Robinson JD, Karam-Hage M, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013;70(5):522–533. PMID: 23536105; PMCID: PMC4128024. doi:10.1001/jamapsychiatry.2013.678
   PubMed Web of Science ®Google Scholar
• Eberg M, Platt RW, Reynier P, Filion KB. Estimation of high-dimensional propensity scores with multiple exposure levels. Pharmacoepidemiol Drug Saf. 2020;29(Suppl 1):53–60. PMID: 31571347. doi:10.1002/pds.4890
   Web of Science ®Google Scholar
• Eisenberg MJ, Grandi SM, Gervais A, et al.; ZESCA Investigators. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. J Am Coll Cardiol. 2013;61:524–532. PMID: 23369417. doi:10.1016/j.jacc.2012.08.1030
   PubMed Web of Science ®Google Scholar
• Garbutt JC, Kampov-Polevoy AB, Kalka-Juhl LS, Gallop RJ. Association of the sweet-liking phenotype and craving for alcohol with the response to naltrexone treatment in alcohol dependence: a randomized clinical trial. JAMA Psychiatry. 2016;73(10):1056–1063. PMID: 27627782. doi:10.1001/jamapsychiatry.2016.2157
   PubMed Web of Science ®Google Scholar
• Graham DJ, By K, McKean S, et al. Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study. Pharmacoepidemiol Drug Saf. 2014;23(11):1205–1212. PMID: 25044169. doi:10.1002/pds.3678
   PubMed Web of Science ®Google Scholar
• Halseth A, Shan K, Gilder K, Malone M, Acevedo L, Fujioka K. Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion. Obes Sci Pract. 2018;4(2):141–152. PMID: 29670752; PMCID: PMC5893468. doi:10.1002/osp4.156
   Web of Science ®Google Scholar
• Hollander P, Gupta AK, Plodkowski R, et al.; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029. PMID: 24144653; PMCID: PMC3836105. doi:10.2337/dc13-0234
   PubMed Web of Science ®Google Scholar
• Jafarinia M, Mohammadi MR, Modabbernia A, et al. Bupropion versus methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder: randomized double-blind study. Hum Psychopharmacol. 2012;27(4):411–418. PMID: 22806822. doi:10.1002/hup.2242
   PubMed Web of Science ®Google Scholar
• Kelty E, Joyce D, Hulse G. A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine. Am J Drug Alcohol Abuse. 2019;45(3):285–291. PMID: 30848965. doi:10.1080/00952990.2018.1545131
   PubMed Web of Science ®Google Scholar
• Kittle J, Lopes RD, Huang M, et al. Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: a systematic retrospective adjudication effort. Clin Cardiol. 2017;40(10):899–906. PMID: 28605035; PMCID: PMC6490529. doi:10.1002/clc.22744
   Web of Science ®Google Scholar
• Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med. 2015;3(10):761–768. PMID: 26355008; PMCID: PMC4593936. doi:10.1016/S2213-2600(15)00320-3
   PubMed Web of Science ®Google Scholar
• Kotz D, Viechtbauer W, Simpson CR, van Schayck OCP, West R, Sheikh A. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. Thorax. 2017;72(10):905–911. PMID: 28473506. doi:10.1136/thoraxjnl-2017-210067
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;108(9):1628–1637. PMID: 23701526. doi:10.1111/add.12208
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Blokhina E, Zvartau E, et al. Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial. Lancet HIV. 2019;6(4):e221–e229. PMID: 30880163; PMCID: PMC6529232. doi:10.1016/S2352-3018(18)30362-X
   Web of Science ®Google Scholar
• Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–1242. PMID: 27028913; PMCID: PMC5454800. doi:10.1056/NEJMoa1505409
   PubMed Web of Science ®Google Scholar
• Maier F, Spottke A, Bach JP, et al. Bupropion for the treatment of apathy in alzheimer disease: a randomized clinical trial. JAMA Netw Open. 2020;3(5):e206027. PMID: 32463470; PMCID: PMC7256670. doi:10.1001/jamanetworkopen.2020.6027
   Web of Science ®Google Scholar
• McIntyre RS, Paron E, Burrows M, et al. Psychiatric safety and weight loss efficacy of naltrexone/bupropion as add-on to antidepressant therapy in patients with obesity or overweight. J Affect Disord. 2021;289:167–176. PMID: 33989969. doi:10.1016/j.jad.2021.04.017
   PubMed Web of Science ®Google Scholar
• Monárrez-Espino J, Galanti MR, Hansson J, Janszky I, Söderberg-Löfdal K, Möller J. Treatment with bupropion and varenicline for smoking cessation and the risk of acute cardiovascular events and injuries: a Swedish case-crossover study. Nicotine Tob Res. 2018;20(5):606–613. PMID: 28595356. doi:10.1093/ntr/ntx131
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990–1004. PMID: 26954408. doi:10.1001/jama.2016.1558
   PubMed Web of Science ®Google Scholar
• Schmitz JM, Green CE, Stotts AL, et al. A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone. Drug Alcohol Depend. 2014;136:100–107. PMID: 24424425; PMCID: PMC3944935. doi:10.1016/j.drugalcdep.2013.12.015
   PubMed Web of Science ®Google Scholar
• Sheridan DC, Lin A, Horowitz BZ. Suicidal bupropion ingestions in adolescents: increased morbidity compared with other antidepressants. Clin Toxicol. 2018;56(5):360–364. PMID: 28944696. doi:10.1080/15563650.2017.1377839
   Web of Science ®Google Scholar
• Spencer TJ, Bhide P, Zhu J, et al. Opiate antagonists do not interfere with the clinical benefits of stimulants in ADHD: a double-blind, placebo-controlled trial of the mixed opioid receptor antagonist naltrexone. J Clin Psychiatry. 2018a;79(1):16m11012. PMID: 28640990; PMCID: PMC6438372. doi:10.4088/JCP.16m11012
   PubMed Web of Science ®Google Scholar
• Svanström H, Pasternak B, Hviid A. Use of varenicline for smoking cessation and risk of serious cardiovascular events: nationwide cohort study. BMJ. 2012;345:e7176. PMID: 23138033; PMCID: PMC3493624. doi:10.1136/bmj.e7176
   PubMed Web of Science ®Google Scholar
• Toh S, Baker MA, Brown JS, Kornegay C, Platt R; Mini-Sentinel Investigators. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration’s Mini-Sentinel program. JAMA Intern Med. 2013;173(9):817–819. PMID: 23529063. doi:10.1001/jamainternmed.2013.3004
   Web of Science ®Google Scholar
• Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140–153. PMID: 33497547; PMCID: PMC8111570. doi:10.1056/NEJMoa2020214
   PubMed Web of Science ®Google Scholar
• Wharton S, Yin P, Burrows M, et al. Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. Int J Obes. 2021;45(8):1687–1695. PMID: 34083744; PMCID: PMC8310797. doi:10.1038/s41366-021-00831-4
   Web of Science ®Google Scholar
• Wellbutrin® (bupropion hydrochloride) tablets. Prescribing information; 2017. Available from: https://fda.gov/drugsatfda_docs/label/2017/018644s052lbl.pdf. Accessed September 21, 2022.
   Google Scholar
• Sposito AC, Bonilha I, Luchiari B, et al. Cardiovascular safety of naltrexone and bupropion therapy: systematic review and meta-analyses. Obes Rev. 2021;22(6):e13224. PMID: 33847068. doi:10.1111/obr.13224
   PubMed Web of Science ®Google Scholar